AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29183357 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief and extensive automated telephony interventions targeting problematic alcohol use
Number of subjects: 248
Study 29183357 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 248
Study 25917942 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Hip Replacement (THR)
Number of subjects: 237
Study 25917942 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement (TKR)
Number of subjects: 237
Study 22986417 — intervention group
Group type: EXPERIMENTAL
Intervention: GIK solution (0.3 ml kg(‐1) h(‐2) containing potassium 80 mEq and regular insulin 325 IU in 500 ml of 50% glucose)
Number of subjects: 66
Study 22986417 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 66
Study 21819251 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes mellitus (T2DM)
Number of subjects: 2163
Study 21819251 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diabetes medications
Number of subjects: 2163
Study 21819251 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin use
Number of subjects: 2163
Study 21819251 — intervention group
Group type: COMPARATOR
Intervention: Control group (no T2DM)
Number of subjects: 2163
Study 18515451 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate 500 mg b.d. for 7 days
Number of subjects: 20
Study 17072963 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebendazole (MBZ) 200 mg taken three times per day (TID) for five days
Number of subjects: 122
Study 17072963 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine (QC) 2 mg/kg bodyweight TID for five days
Number of subjects: 122
Study 17072963 — intervention group
Group type: COMPARATOR
Intervention: Quinacrine (QC)
Number of subjects: 122
Study 14555565 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 500 microg bid using a spacer device
Number of subjects: 751
Study 14555565 — intervention group
Group type: COMPARATOR
Intervention: Placebo inhaler
Number of subjects: 751
Study 14555565 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP)
Number of subjects: 751
Study 14555565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 751
Study 10743449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 40 micrograms kg‐1 orally 1 h before operation (group A)
Number of subjects: 120
Study 10743449 — intervention group
Group type: COMPARATOR
Intervention: No premedication (group B)
Number of subjects: 120
Study 8883676 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual muscle test for supraspinatus muscle at 90 degrees of scapular elevation and +45 degrees of external rotation
Number of subjects: 11
Study 8883676 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual muscle test for infraspinatus muscle at 0 degree of scapular elevation and -45 degrees of internal rotation
Number of subjects: 11
Study 8883676 — intervention group
Group type: EXPERIMENTAL
Intervention: Gerber push-off test for subscapularis muscle
Number of subjects: 11
Study 1328941 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine 30 mg/kg body-weight (30-min infusion)
Number of subjects: 25
Study 1328941 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine doses of 5, 10, and 20 mg/kg body-weight
Number of subjects: 25
Study 1328941 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly doses of 5-10 mg/kg of desferrioxamine
Number of subjects: 25
Study 3899671 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (50 mg hydrochlorothiazide and labetalol)
Number of subjects: 0
Study 3899671 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (50 mg hydrochlorothiazide, 200 mg atenolol and prazosin)
Number of subjects: 0
Study 3899671 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31450969 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine visits
Number of subjects: 45
Study 31450969 — intervention group
Group type: COMPARATOR
Intervention: In-office visits
Number of subjects: 45
Study 29105204 — intervention group
Group type: EXPERIMENTAL
Intervention: Food images
Number of subjects: 87
Study 29105204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive eating disorder symptoms and binge eating
Number of subjects: 87
Study 26460893 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 130
Study 26460893 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Enhancement Program (HEP)
Number of subjects: 130
Study 26460893 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 130
Study 26460893 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR and HEP
Number of subjects: 130
Study 24823888 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced, online educational course on complex nursing care of hospitalized patients on basal-bolus insulin
Number of subjects: 0
Study 24823888 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22982903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid 500 mg
Number of subjects: 40
Study 22982903 — intervention group
Group type: COMPARATOR
Intervention: Sevelamer 1600 mg
Number of subjects: 40
Study 20473577 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium- and long-chain triacylglycerols (MLCT) 25-30 g/day
Number of subjects: 101
Study 20473577 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (LCT) 25-30 g/day
Number of subjects: 101
Study 18675742 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch 5%
Number of subjects: 46
Study 18675742 — intervention group
Group type: COMPARATOR
Intervention: Vehicle patch
Number of subjects: 46
Study 16786754 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term low dose glucocorticosteroids (GCS), dosage and duration not specified
Number of subjects: 0
Study 14560861 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol 1.5 mg/kg
Number of subjects: 79
Study 14560861 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0.1 mg/kg
Number of subjects: 79
Study 10469771 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplemented formula
Number of subjects: 0
Study 10469771 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA plus arachidonic acid supplemented formula
Number of subjects: 0
Study 10469771 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo (no LCPUFA)
Number of subjects: 0
Study 10469771 — intervention group
Group type: COMPARATOR
Intervention: Breastfed infants (control group)
Number of subjects: 0
Study 8915561 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20-60 mg/day
Number of subjects: 42
Study 8915561 — intervention group
Group type: COMPARATOR
Intervention: Phenelzine 45-90 mg/day
Number of subjects: 42
Study 1910998 — intervention group
Group type: EXPERIMENTAL
Intervention: metrizamide
Number of subjects: 38
Study 1910998 — intervention group
Group type: COMPARATOR
Intervention: iohexol
Number of subjects: 38
Study 6349537 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole with Tegafur
Number of subjects: 0
Study 6349537 — intervention group
Group type: COMPARATOR
Intervention: Levamisole with 5-Fluorouracil
Number of subjects: 0
Study 30178193 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab plus lenalidomide plus dexamethasone
Number of subjects: 0
Study 30178193 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 0
Study 26903176 — intervention group
Group type: EXPERIMENTAL
Intervention: NEXit core program with 157 text messages for 12 weeks
Number of subjects: 1590
Study 26903176 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 1 text every 2 weeks
Number of subjects: 1590
Study 23848167 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG) - acute tri-set resistance training protocol with two combinations of three exercises at 75% of 1RM for six to eight repetitions
Number of subjects: 18
Study 23848167 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 18
Study 23848167 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 18
Study 23848167 — intervention group
Group type: COMPARATOR
Intervention: Exercise Group (EG) compared to Control Group (CG)
Number of subjects: 18
Study 22419420 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi training (18 weeks, 45 minutes twice a week)
Number of subjects: 40
Study 20138583 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet behavioral weight-loss program
Number of subjects: 66
Study 18608836 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning group (07:00-09:00 h)
Number of subjects: 27
Study 18608836 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening group (17:00-19:00 h)
Number of subjects: 27
Study 18608836 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 27
Study 16210311 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 240
Study 16210311 — intervention group
Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (cLMA)
Number of subjects: 240
Study 12401823 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient self management
Number of subjects: 78
Study 12401823 — intervention group
Group type: COMPARATOR
Intervention: Routine primary care management
Number of subjects: 78
Study 10089949 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 micrograms/kg by intravenous infusion
Number of subjects: 0
Study 10089949 — intervention group
Group type: COMPARATOR
Intervention: No treatment (group NG)
Number of subjects: 0
Study 8521310 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol 2.5 mg.kg‐1
Number of subjects: 60
Study 8521310 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol 3 mg.kg‐1
Number of subjects: 60
Study 8521310 — intervention group
Group type: EXPERIMENTAL
Intervention: propofol 3.5 mg.kg‐1
Number of subjects: 60
Study 2281103 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet scintigraphy (PS)
Number of subjects: 104
Study 2281103 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance plethysmography (IPG)
Number of subjects: 104
Study 2281103 — intervention group
Group type: EXPERIMENTAL
Intervention: Color flow duplex ultrasound (U)
Number of subjects: 104
Study 2281103 — intervention group
Group type: COMPARATOR
Intervention: Venography (V)
Number of subjects: 104
Study 7446914 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia
Number of subjects: 60
Study 7446914 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal analgesia
Number of subjects: 60
Study 7446914 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoas compartment block
Number of subjects: 60
Study 30985703 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaungo (JUG) ointment applied on irradiated skin for 6 weeks, twice a day
Number of subjects: 80
Study 30985703 — intervention group
Group type: COMPARATOR
Intervention: General supportive care (GSC)
Number of subjects: 80
Study 30985703 — intervention group
Group type: EXPERIMENTAL
Intervention: Jaungo (JUG) ointment
Number of subjects: 80
Study 27311449 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided interscalene brachus plexus block (ISB) combined with arthroscopy-guided suprascapular nerve block (SSNB)
Number of subjects: 48
Study 27311449 — intervention group
Group type: COMPARATOR
Intervention: Ultrasound-guided interscalene brachus plexus block (ISB) alone
Number of subjects: 48
Study 25872590 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG 1064 nM laser application (4 sessions)
Number of subjects: 64
Study 25872590 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 64
Study 23692617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast-velocity concentric isokinetic resistance training (FV)
Number of subjects: 18
Study 23692617 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 18
Study 21869688 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone 2 mg/d
Number of subjects: 225
Study 21869688 — intervention group
Group type: EXPERIMENTAL
Intervention: sodium valproate 600 mg/d
Number of subjects: 225
Study 21869688 — intervention group
Group type: EXPERIMENTAL
Intervention: buspirone 30 mg/d
Number of subjects: 225
Study 21869688 — intervention group
Group type: EXPERIMENTAL
Intervention: trazodone 100 mg/d
Number of subjects: 225
Study 21869688 — intervention group
Group type: EXPERIMENTAL
Intervention: thyroid hormone 80 mg/d
Number of subjects: 225
Study 19362361 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of artemether-lumefantrine (n=217)
Number of subjects: 437
Study 19362361 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of artemether-lumefantrine (n=189)
Number of subjects: 437
Study 19362361 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=208)
Number of subjects: 437
Study 19362361 — intervention group
Group type: COMPARATOR
Intervention: Standard care (n=176)
Number of subjects: 437
Study 17585029 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein isolate (SPI+) (107 mg/d isoflavones)
Number of subjects: 58
Study 17585029 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-washed soy protein isolate (SPI-) (<6 mg/d isoflavones)
Number of subjects: 58
Study 17585029 — intervention group
Group type: COMPARATOR
Intervention: Milk protein isolate (0 mg/d isoflavones)
Number of subjects: 58
Study 14718883 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior open bite extraction treatment
Number of subjects: 31
Study 14718883 — intervention group
Group type: COMPARATOR
Intervention: Control group with normal occlusion
Number of subjects: 31
Study 14718883 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 31
Study 11468762 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10736082 — intervention group
Group type: COMPARATOR
Intervention: Tropisetron alone
Number of subjects: 125
Study 10736082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron plus dexamethasone
Number of subjects: 125
Study 8922769 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.05 mg.kg‐1
Number of subjects: 200
Study 8922769 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg.kg‐1
Number of subjects: 200
Study 8922769 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.10 mg.kg‐1
Number of subjects: 200
Study 8922769 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.15 mg.kg‐1
Number of subjects: 200
Study 8922769 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 0.20 mg.kg‐1
Number of subjects: 200
Study 1359260 — intervention group
Group type: EXPERIMENTAL
Intervention: Excimer laser
Number of subjects: 116
Study 1359260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser
Number of subjects: 116
Study 1359260 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA
Number of subjects: 116
Study 1359260 — intervention group
Group type: COMPARATOR
Intervention: All treatments (laser and PTA)
Number of subjects: 116
Study 3892345 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine and prednisone
Number of subjects: 63
Study 3892345 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine and prednisone
Number of subjects: 63
Study 31547966 — intervention group
Group type: EXPERIMENTAL
Intervention: TightRope fixation
Number of subjects: 12
Study 31547966 — intervention group
Group type: COMPARATOR
Intervention: Screw fixation
Number of subjects: 12
Study 29363356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (n = 51)
Number of subjects: 103
Study 29363356 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (n = 52)
Number of subjects: 103
Study 26868497 — intervention group
Group type: EXPERIMENTAL
Intervention: LDCT1 (annual screening)
Number of subjects: 2303
Study 26868497 — intervention group
Group type: COMPARATOR
Intervention: LDCT2 (biennial screening)
Number of subjects: 2303
Study 24310562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (750 mg)
Number of subjects: 9
Study 24310562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 22499825 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (needles inserted at points HT7, PC6, CV17, GV20 and Yintang)
Number of subjects: 43
Study 22499825 — intervention group
Group type: COMPARATOR
Intervention: Control group (needles inserted in areas near but not corresponding to acupuncture points)
Number of subjects: 43
Study 22131689 — intervention group
Group type: EXPERIMENTAL
Intervention: Arkapushpa Taila Uttarbasti and Krishna Tila Kwatha administered simultaneously
Number of subjects: 31
Study 22131689 — intervention group
Group type: COMPARATOR
Intervention: Krishna Tila Kwatha administered orally
Number of subjects: 31
Study 22131689 — intervention group
Group type: COMPARATOR
Intervention: Placebo wheat powder administered orally
Number of subjects: 31
Study 17114187 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nasal airflow (high flow unhumidified air with 20 p.p.m. nitric oxide gas)
Number of subjects: 12
Study 17114187 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral head fanning
Number of subjects: 12
Study 17114187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined effect of airflow and fanning
Number of subjects: 12
Study 17114187 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 12
Study 16046988 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (administered 4 hours and 1 hour before ERCP)
Number of subjects: 701
Study 16046988 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 701
Study 12172337 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluoxetine (40-60 mg/day)
Number of subjects: 101
Study 12172337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus desipramine (25-50 mg/day)
Number of subjects: 101
Study 12172337 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine plus lithium (300-600 mg/day)
Number of subjects: 101
Study 10225495 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Northland intervention
Number of subjects: 2351
Study 10225495 — intervention group
Group type: COMPARATOR
Intervention: Reference condition
Number of subjects: 2351
Study 7787916 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who controlled their bed position (experimental group)
Number of subjects: 54
Study 7787916 — intervention group
Group type: COMPARATOR
Intervention: Patients who remained flat in bed (control group)
Number of subjects: 54
Study 2273939 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (bicycling on a bicycle ergometer at 50% of MWC for 10 min, followed by 10 min at 80% of MWC)
Number of subjects: 7
Study 30219843 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 860
Study 25854499 — intervention group
Group type: EXPERIMENTAL
Intervention: Early full weight-bearing (11-day protocol)
Number of subjects: 120
Study 25854499 — intervention group
Group type: COMPARATOR
Intervention: 20-kg partial weight-bearing for 6 weeks
Number of subjects: 120
Study 25495361 — intervention group
Group type: EXPERIMENTAL
Intervention: Project UPLIFT (mindfulness-based cognitive therapy)
Number of subjects: 128
Study 25495361 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 128
Study 22858191 — intervention group
Group type: EXPERIMENTAL
Intervention: AGE (300 mg/tablet) plus CoQ10 (30 mg/tablet)
Number of subjects: 65
Study 22858191 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 20561879 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathing during weaning trials
Number of subjects: 30
Study 20561879 — intervention group
Group type: COMPARATOR
Intervention: Nocturnal bathing
Number of subjects: 30
Study 20561879 — intervention group
Group type: COMPARATOR
Intervention: Bathing within 1 hour before a trial
Number of subjects: 30
Study 19125989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone turnover markers (BTM)
Number of subjects: 0
Study 19125989 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone mineral density (BMD)
Number of subjects: 0
Study 17329409 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol CR
Number of subjects: 168
Study 17329409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 168
Study 14732755 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCABG
Number of subjects: 60
Study 14732755 — intervention group
Group type: COMPARATOR
Intervention: ONCABG
Number of subjects: 60
Study 14732755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 11180315 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 9432335 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) for 2 weeks
Number of subjects: 175
Study 9432335 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) + Metronidazole (500 mg bid) for 1 week
Number of subjects: 175
Study 9432335 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg bid) + Amoxicillin (1 gm bid) + Clarithromycin (500 mg bid) for 1 week
Number of subjects: 175
Study 9432335 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 175
Study 7945542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 300 mg daily with ranitidine 150 mg daily
Number of subjects: 32
Study 7945542 — intervention group
Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) 300 mg daily without ranitidine (Placebo)
Number of subjects: 32
Study 3283595 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 75
Study 3283595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 31197264 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Amiloride/Hydrochlorothiazide
Number of subjects: 9885
Study 31197264 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Telmisartan
Number of subjects: 9885
Study 31197264 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin group
Number of subjects: 9885
Study 31197264 — intervention group
Group type: COMPARATOR
Intervention: Routine intervention group
Number of subjects: 9885